Top Markets
#1 TENDIES TENDIES +60.15%
#2 Threshold Network Threshold Network +48.72%
#3 Akedo Akedo +24.88%
#4 Cash Cat Cash Cat +21.86%
#5 Kinetiq Kinetiq +16.38%
#6 OSK OSK +16.37%
#7 Maple Finance Maple Finance +13.27%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Magma Finance Magma Finance +12.46%
#10 Falcon Finance Falcon Finance +11.62%
Coin of the day
TENDIES TENDIES
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Kedudukan dalam Saham #17262
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Harga Saham
$0.873
Modal Pasaran
$257.19M
Perubahan (1 hari)
-0.78%
Perubahan (1 tahun)
-15.24%
Negara
US
Perdagangan Invivyd, Inc. (IVVD)

Kategori

Healthcare
Pendapatan untuk Invivyd, Inc. (IVVD)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Invivyd, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Invivyd, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH